Table 2.
Treatments and clinical outcomes during follow-up according to diabetes status in propensity score-matched cohort.
| All | No diabetes | Diabetes | P | n | |
|---|---|---|---|---|---|
| Treatment introduced during hospitalization, n (%) | |||||
| Chloroquine or hydroxychloroquine | 197 (16.3) | 97 (16.1) | 100 (16.6) | 0.88 | 1206 |
| Antivirals | 148 (12.3) | 70 (11.6) | 78 (12.9) | 0.54 | 1206 |
| Corticosteroids | 93 (7.71) | 53 (8.79) | 40 (6.63) | 0.2 | 1206 |
| Antibiotics | 915 (75.9) | 453 (75.1) | 462 (76.6) | 0.59 | 1206 |
| Anticoagulation | 1020 (90.5) | 503 (90.1) | 517 (90.9) | 0.76 | 1127 |
| Prophylactic doses | 751 (66.6) | 359 (64.3) | 392 (68.9) | 0.12 | 1127 |
| Curative doses | 269 (23.9) | 144 (25.8) | 125 (22.0) | 0.15 | 1127 |
| Respiratory support, n (%) | |||||
| Low-dose oxygen | 804 (66.7) | 407 (67.5) | 397 (65.8) | 0.58 | 1206 |
| High-flow oxygen delivery | 210 (17.4) | 102 (16.9) | 108 (17.9) | 0.7 | 1206 |
| High-flow nasal cannula | 69 (5.72) | 42 (6.97) | 27 (4.48) | 0.08 | 1206 |
| Non-invasive ventilation | 35 (2.90) | 17 (2.82) | 18 (2.99) | 1 | 1206 |
| Invasive mechanical ventilation | 169 (14.0) | 74 (12.3) | 95 (15.8) | 0.1 | 1206 |
| Outcomes | |||||
| Hospital stay, daysa | 8.00 [5.00, 13.0] | 8.00 [5.00, 13.0] | 8.00 [5.00, 13.0] | 0.47 | 745 |
| Primary outcome, n (%) | 406 (33.7) | 192 (31.8) | 214 (35.5) | 0.2 | 1206 |
| All deaths, n (%) | 202 (16.7) | 91 (15.1) | 111 (18.4) | 0.14 | 1206 |
| Transfer to ICU, n (%) | 244 (20.2) | 118 (19.6) | 126 (20.9) | 0.62 | 1206 |
| Death in ICU, n (%) | 40 (3.3) | 17 (2.8) | 23 (3.8) | 0.42 | 1206 |
| Death with no transfer to ICU, n (%) | 162 (13.4) | 74 (12.3) | 88 (14.6) | 0.27 | 1206 |
a
Data not normally distributed are presented as medians [25th, 75th percentiles].